Trevi Therapeutics, Inc. TRVI Ratios & Valuation
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Returns | ||||||
| Return on equity | -33.6%+21.5pp | -30.2%+22.4pp | -36.9%+22.8pp | -35.7%+12.3pp | -55.1%-16.6pp | |
| Return on assets | -31.8%+19.2pp | -28.1%+19.7pp | -34.2%+19.6pp | -33.5%+10.8pp | -51%-16.6pp | |
| Return on invested capital | -45%+27.5pp | -42.6%+44.6pp | -57.8%+30.5pp | -75.3%-12.5pp | -72.5%-22.0pp | |
| Liquidity | ||||||
| Current ratio | 24.8×+9.4× | 19.7×+9.2× | 21.9×+14.6× | 22.4×+11.7× | 15.4×+0.8× | |
| Quick ratio | 24.8×+9.4× | 19.7×+9.2× | 21.9×+14.6× | 22.4×+11.7× | 15.4×+0.8× | |
| Cash ratio | 2.7×-0.1× | 1.9×-1.3× | 6.3×+4.5× | 12.7×+10.7× | 2.8×+0.2× | |
| Leverage | ||||||
| Debt-to-equity | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | |
| Debt-to-assets | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | |
| Per Share | ||||||
| Book value per share | $1.18+39.8% | $1.36+39.2% | $1.31+125% | $1.52+133% | $0.85+16.3% | |
| Valuation | ||||||
| Market capitalization | $1.53B+152% | $1.61B+336% | $1.11B+230% | $702.53M+137% | $608.13M+77.2% | |
| Enterprise value | $1.51B+157% | $1.59B+374% | $1.06B+228% | $586.36M+106% | $589.71M+78.3% | |
| Price / book | 8.9×+2.8× | 8.8×+5.1× | 5.9×+0.1× | 3.5×-0.9× | 6.1×+1.4× | |
| Earnings yield | -3%+4.8pp | -2.7%+10.3pp | -4.1%+9.0pp | -6.7%+6.3pp | -7.8%+2.0pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Trevi Therapeutics, Inc.'s ratios come from?
- Every ratio is computed from Trevi Therapeutics, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.